Eaton Vance Management Has $106.66 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Eaton Vance Management lifted its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 0.6% in the first quarter, according to the company in its most recent filing with the SEC. The fund owned 1,650,389 shares of the biopharmaceutical company’s stock after buying an additional 10,367 shares during the quarter. Eaton Vance Management’s holdings in Gilead Sciences were worth $106,664,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of GILD. Rockbridge Investment Management LCC increased its position in Gilead Sciences by 236.5% during the fourth quarter. Rockbridge Investment Management LCC now owns 535 shares of the biopharmaceutical company’s stock worth $31,000 after acquiring an additional 376 shares during the period. Elmwood Wealth Management Inc. bought a new position in Gilead Sciences during the first quarter worth about $35,000. JJJ Advisors Inc. increased its position in Gilead Sciences by 131.5% during the first quarter. JJJ Advisors Inc. now owns 558 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 317 shares during the period. Burleson & Company LLC bought a new position in Gilead Sciences during the first quarter worth about $43,000. Finally, Alpha DNA Investment Management LLC bought a new position in Gilead Sciences during the fourth quarter worth about $47,000. Institutional investors own 76.78% of the company’s stock.

A number of equities analysts recently commented on GILD shares. TheStreet raised shares of Gilead Sciences from a “c” rating to a “b-” rating in a research report on Tuesday, March 30th. Morgan Stanley raised their target price on shares of Gilead Sciences from $81.00 to $83.00 and gave the company an “overweight” rating in a report on Monday, May 3rd. Redburn Partners raised shares of Gilead Sciences from a “neutral” rating to a “buy” rating in a report on Tuesday, March 30th. Zacks Investment Research raised shares of Gilead Sciences from a “sell” rating to a “hold” rating and set a $69.00 target price on the stock in a report on Wednesday, May 5th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $80.00 target price on shares of Gilead Sciences in a report on Friday, May 7th. Ten research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Gilead Sciences currently has an average rating of “Buy” and a consensus price target of $99.22.

NASDAQ:GILD opened at $68.41 on Thursday. The stock’s 50 day simple moving average is $67.84. The company has a current ratio of 1.37, a quick ratio of 1.18 and a debt-to-equity ratio of 1.55. Gilead Sciences, Inc. has a one year low of $56.56 and a one year high of $77.25. The firm has a market cap of $85.80 billion, a P/E ratio of 9.23, a PEG ratio of 0.64 and a beta of 0.38.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, April 29th. The biopharmaceutical company reported $2.08 EPS for the quarter, topping the consensus estimate of $2.06 by $0.02. The business had revenue of $6.42 billion for the quarter, compared to the consensus estimate of $6.78 billion. Gilead Sciences had a net margin of 1.18% and a return on equity of 51.91%. On average, equities analysts predict that Gilead Sciences, Inc. will post 7.05 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, June 29th. Stockholders of record on Tuesday, June 15th were given a $0.71 dividend. The ex-dividend date of this dividend was Monday, June 14th. This represents a $2.84 dividend on an annualized basis and a dividend yield of 4.15%. Gilead Sciences’s dividend payout ratio (DPR) is currently 40.06%.

In other news, Director Richard James Whitley sold 20,282 shares of the business’s stock in a transaction that occurred on Monday, May 3rd. The shares were sold at an average price of $64.57, for a total value of $1,309,608.74. Following the transaction, the director now owns 51,404 shares in the company, valued at approximately $3,319,156.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.12% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm’s primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.

Featured Story: What is a CD ladder?

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.